Immunocore Holdings plc financial data

Symbol
IMCR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
90 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Immunocore Ltd (to 2/1/2021)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 458 %
Quick Ratio 2.23 %
Debt-to-equity 152 %
Return On Equity -12.8 %
Return On Assets -5.09 %
Operating Margin -23 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50M shares
Common Stock, Shares, Outstanding 50M shares
Entity Public Float 2.7B USD
Common Stock, Value, Issued 135K USD
Weighted Average Number of Shares Outstanding, Basic 50M shares +1.81%
Weighted Average Number of Shares Outstanding, Diluted 52.8M shares -2.49%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 296M USD +23.7%
Cost of Revenue 2.6M USD +62.3%
Research and Development Expense 207M USD +22%
Operating Income (Loss) -68.1M USD +39.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -53.8M USD +734%
Income Tax Expense (Benefit) -6.71M USD -1410%
Net Income (Loss) Attributable to Parent -47M USD +864%
Earnings Per Share, Basic -0.95 USD/shares +750%
Earnings Per Share, Diluted -0.95 USD/shares +750%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 538M USD
Marketable Securities, Current 364M USD
Accounts Receivable, after Allowance for Credit Loss, Current 63.7M USD
Inventory, Net 4.52M USD
Other Assets, Current 9.71M USD +168%
Assets, Current 1.01B USD
Deferred Income Tax Assets, Net 12.7M USD
Property, Plant and Equipment, Net 9.16M USD
Operating Lease, Right-of-Use Asset 39.7M USD +621%
Other Assets, Noncurrent 17.2M USD
Assets 1.08B USD
Accounts Payable, Current 19.7M USD
Employee-related Liabilities, Current 12.3M USD
Liabilities, Current 266M USD
Operating Lease, Liability, Noncurrent 41.3M USD
Liabilities 707M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -31.2M USD
Retained Earnings (Accumulated Deficit) -772M USD
Stockholders' Equity Attributable to Parent 378M USD +6.14%
Liabilities and Equity 1.08B USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.59M USD -144%
Net Cash Provided by (Used in) Financing Activities 396M USD +6351%
Net Cash Provided by (Used in) Investing Activities -430K USD +85.7%
Common Stock, Shares, Issued 50M shares
Common Stock, Par or Stated Value Per Share 0 GBP/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 538M USD +21.1%
Deferred Tax Assets, Valuation Allowance 83.1M USD -3.83%
Deferred Tax Assets, Gross 95.3M USD +3.09%
Operating Lease, Liability 42.4M USD +670%
Depreciation 1.01M USD +6.2%
Payments to Acquire Property, Plant, and Equipment 430K USD -85.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.8M USD
Lessee, Operating Lease, Liability, to be Paid 69.2M USD
Property, Plant and Equipment, Gross 61.5M USD +15%
Operating Lease, Liability, Current 1.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.64M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.38M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 26.8M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.54M USD
Deferred Tax Assets, Operating Loss Carryforwards 74.9M USD +2.54%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.82M USD
Additional Paid in Capital 1.18B USD
Interest Expense 3.24M USD +159%